Cited by 711SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingAnimal Virus Infections Studies

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Open access

Nie, Jianhui, Li, Qianqian, Wu, Jiajing, Zhao, Chenyan, Hao, Huan, Liu, Huan, Zhang, Li, Nie, Lingling, Qin, Haiyang, Wang, Meng, Lu, Qiong, Li, Xiaoyu, Sun, Qiyu, Liu, Junkai, Fan, Changfa, Huang, Weijin, Xu, Miao, Wang, Youchun·2020·Emerging Microbes & Infections

DOI 10.1080/22221751.2020.1743767PMC PMC7144318

Open this paper in CoChat — free account

Abstract

Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1080/22221751.2020.1743767

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. Verification of the incorporaiton of SARS-CoV-2 spike protein in the pseudovirus. The surface proteins of the particle were investigated using western blotting (A), from left to right lane showing VSV pseudovirus, medium control and SARS-CoV-2 pseudovirus. The VSV pseudotyped virus and cell culture medium were prepared with the same procedure and used as negative control and pseudovirus negative control. The SARS-CoV-2 pseudovirus, together with G*ΔG-VSV, were tested against VSV G specific antibody (B).CC BY · PubMed Central

Figure 2. Selection of the cell line. Six types of cells were tested for VSV (A), and SARS-CoV-2 (B) pseudoviruses. The y-axis showed the absolute RLU value detected 24 h after pseudovirus infection. Cell backgrounds without pseudovirus infection were shown in figure C.CC BY · PubMed Central

Figure 3. Optimization of cell numbers for neutralization. (A) Effect of cells numbers on the titration of pseudovirus. The y-axis showed the RLU fold over the cell background. (B) Effect of cells numbers on the neutralization. Cell numbers and corresponding R2 values were list in the tables. A serum sample from a healthy individual was tested as negative control shown in black lines and symbols.CC BY · PubMed Central

Figure 4. Optimization of virus dose for neutralization. The viral inocula with a dose range starting from 41 to 1300 TCID50/well were tested for SARS-CoV-2 PBNA. A serum sample from a healthy individual was tested as negative control shown in black lines and symbols.CC BY · PubMed Central

Figure 5. Validation of the SARS-CoV-2 PBNA. (A) Specificity of the PBNA. A negative sample panel of seventy-four human and forty-six mouse serum samples were used to determine the specificity of this assay. (B) Inhibition curves for two SARS-CoV-2 convalescent patient serum samples and two negative serum samples derived from human and mouse. Typical four-parameter inhibition curves were observed for these two samples between log-transformed dilution and inhibition rate. The initial dilutions for positive and negative samples were 1:30 and 1:10 respectively, followed by 3-fold serial dilution. (C) Linear range for the PBNA. When the inhibition rate is in the range of 20%–80%, there is a linear relationship between the readout of the test sample and its dilution. (D) Reproducibility of the PBNA. A mixture of two SARS-CoV-2 coalescent patient serum samples was tested a total of 18 times on individual plates in three independent runs.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Self-citation
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Self-citation
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Self-citation
The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China
Hui, D. S., I Azhar, E., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., Ippolito, G., Mchugh, T. D., Memish, Z. A., Drosten, C., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.01.009 · Cited by 3,809
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
Chan, J. F., Kok, K., Zhu, Z., Chu, H., To, K. K., Yuan, S., & Yuen, K. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,127
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Chen, Y. Z., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,069
Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China
Wu, A., Peng, Y., Huang, B., Ding, X. L., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.02.001 · Cited by 2,386
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,678
The Novel Coronavirus Originating in Wuhan, China
Phelan, A., Katz, R., & Gostin, L. O. (2020) · JAMA · doi:10.1001/jama.2020.1097 · Cited by 1,210
Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines
Whitt, M. A. (2010) · Journal of Virological Methods · doi:10.1016/j.jviromet.2010.08.006 · Cited by 431

Show all 27 references

Sorted by citations

Items 401–500 of 696

Construction and immunogenicity of an mRNA vaccine against chikungunya virus
Liu, J., Lu, X., Li, X., Huang, W., Fang, E., Li, W., Liu, X., Liu, M., Li, J., Li, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129118 · Cited by 10
Self-citation
High-throughput screening of spike variants uncovers the key residues that alter the affinity and antigenicity of SARS-CoV-2
Luo, Y., Liu, S., Xue, J., Yang, Y., Zhao, J., Sun, Y., Wang, B., Yin, S., Li, J., Xia, Y., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00534-2 · Cited by 10
Self-citation
SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD
Septisetyani, E. P., Prasetyaningrum, P. W., Anam, K., & Santoso, A. (2021) · Immune Network · doi:10.4110/in.2021.21.e39 · Cited by 11
The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice
Hu, L., Xu, Y., Wu, L., Feng, J., Zhang, L., Tang, Y., Zhao, X., Mai, R., Chen, L., Mei, L., et al. (2022) · Viruses · doi:10.3390/v14050854 · Cited by 11
Self-citation
Diagnostic TR-FRET assays for detection of antibodies in patient samples
Yue, H., Nowak, R. P., Overwijn, D., Payne, N. C., Fischinger, S., Atyeo, C. G., Lam, E. C., Denis, K. S., Brais, L. K., Konishi, Y., et al. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100421 · Cited by 11
A Newly Identified Spike Protein Targeted Linear B‐Cell Epitope Based Dissolvable Microneedle Array Successfully Eliciting Neutralizing Activities against SARS‐CoV‐2 Wild‐Type Strain in Mice
Li, L., Zhao, Z., Yang, X., Su, Z., Li, W., Chen, S., Wang, L., Sun, T., Du, C., Li, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202207474 · Cited by 10
Self-citation
Immunity against SARS-CoV-2: walking to the vaccination
Hernández, C. R., & Sanz, J. C. (2020) · Revista Española de Quimioterapia · doi:10.37201/req/086.2020 · Cited by 10
Self-Assembly of Single-Virus SERS Hotspots for Highly Sensitive In Situ Detection of SARS-CoV-2 on Solid Surfaces
Song, K., Xue, W., Li, X., Chang, Y., & Liu, M. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c01607 · Cited by 9
Self-citation
Effect of different human tissue processing techniques on SARS-CoV-2 inactivation-review
Paggiaro, A. O., de Carvalho, V. F., & Gemperli, R. (2020) · Cell and Tissue Banking · doi:10.1007/s10561-020-09869-6 · Cited by 9
Expression of NKG2A inhibitory receptor on cytotoxic lymphocytes as an indicator of severity in Corona Virus Disease 2019 (COVID-19) patients
Yasin, M. M., Shehata, I. H., Elsheikh, N. G., & Elsayed, M. (2021) · Egyptian journal of Immunology · doi:10.55133/eji.280116 · Cited by 9
Identification of Kaempferol as Viral Entry Inhibitor and DL-Arginine as Viral Replication Inhibitor from Selected Plants of Indian Traditional Medicine against COVID-19: An in silico Guided in vitro Approach
Adithya, J., Murali, M., Nair, B., Benny, F., Mani, R. P., Suresh, D., Aneesh, T. P., Areekkara, A. N., & Nath, L. R. (2023) · Current Computer - Aided Drug Design · doi:10.2174/1573409919666230112123213 · Cited by 9
Plant Extracts and SARS-CoV-2: Research and Applications
Heleno, S. A., Carocho, M., Reis, F. S., Pires, T. C. S. P., Pintado, M., Ferreira, I. C. F. R., & Barros, L. (2023) · Life · doi:10.3390/life13020386 · Cited by 10
An Evaluation of a SARS-CoV-2 Pseudovirus Neutralization Test and A Comparison to a SARS-CoV-2 Surrogate Virus Neutralization Test in a COVID-19 Long-Term Follow-Up Cohort
Gillot, C., Favresse, J., David, C., Maloteau, V., Dogné, J., & Douxfils, J. (2024) · Microbiology Research · doi:10.3390/microbiolres15010028 · Cited by 9
Optimization and validation of a virus‐like particle pseudotyped virus neutralization assay for SARS‐CoV‐2
Liu, S., Zhang, L., Fu, W., Liang, Z., Yu, Y., Li, T., Tong, J., Liu, F., Nie, J., Lu, Q., et al. (2024) · MedComm · doi:10.1002/mco2.615 · Cited by 9
Self-citation
Methods to Identify Immunogenic Peptides in SARS‐CoV‐2 Spike and Protective Monoclonal Antibodies in COVID‐19 Patients
Li, L., Gao, M., Li, J., Zu, S., Wang, Y., Chen, C., Wan, D., Duan, J., Aliyari, R., Wang, J., et al. (2021) · Small Methods · doi:10.1002/smtd.202100058 · Cited by 9
Self-citation
Evidence Mapping of 23 Systematic Reviews of Traditional Chinese Medicine Combined With Western Medicine Approaches for COVID-19
Zhang, T., Li, X., Chen, Y., Zhao, L., Tian, J., & Zhang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.807491 · Cited by 9
Self-citation
A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies
Pi-Estopiñán, F., Pérez, M. T. A., Fraga, A., Bergado, G., Díaz-Ordaz, G. D., Orosa-Vázquez, I., Díaz-Hernández, M., Solozabal, J., Rodríguez, L. M., García-Rivera, D., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.044 · Cited by 9
Identification of SARS-CoV-2 Neutralizing Antibody with Pseudotyped Virus-based Test on HEK-293T hACE2 Cells
Gillot, C., Favresse, J., Maloteau, V., Dogné, J.-M., & Douxfils, J. (2022) · BIO-PROTOCOL · doi:10.21769/bioprotoc.4377 · Cited by 9
Human ACE2 Genetic Polymorphism Affecting SARS-CoV and SARS-CoV-2 Entry into Cells
Hattori, T., Saito, T., Okuya, K., Takahashi, Y., Miyamoto, H., Kajihara, M., Igarashi, M., & Takada, A. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00870-22 · Cited by 9
Down‐regulation of SARS‐CoV‐2 neutralizing antibodies in vaccinated smokers
Zhang, J., Teng, F., Zhang, X., Wang, H., Liang, T., Guo, S., & Yu, X. (2022) · MedComm · doi:10.1002/mco2.166 · Cited by 9
Thiopurines inhibit coronavirus Spike protein processing and incorporation into progeny virions
Pringle, E. S., Duguay, B. A., Bui-Marinos, M. P., Mulloy, R. P., Landreth, S. L., Desireddy, K. S., Dolliver, S. M., Ying, S., Caddell, T., Tooley, T. H., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010832 · Cited by 10
Preclinical Toxicity and Immunogenicity of a COVID-19 Vaccine (ZF2001) in Cynomolgus Monkeys
Yang, H., Pan, W., Chen, G., Huang, E., Lu, Q., Chen, Y., Chen, Y., Yang, Z., Wen, L., Zhang, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10122080 · Cited by 10
Self-citation
Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization
Su, W., Chen, Z.-Y., Chang, Y.-S., Jeng, K.-S., Le, U. N. P., Chou, Y., Kuo, L.-L., Melano, I., Jesse, Wang, W., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105744 · Cited by 9
The clinical and bioinformatics analysis for the role of antihypertension drugs on mortality among patients with hypertension hospitalized with COVID‐19
Zhao, L., Li, Y., Yi, W., Yan, K., Yang, C., Sridhar, R., Li, R., Tan, R., Fan, G., Dai, M., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27914 · Cited by 9
Advances in Surrogate Neutralization Tests for High-Throughput Screening and the Point-of-Care
Streif, S., & Baeumner, A. J. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c00666 · Cited by 8
SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19
Prendecki, M. F., Clarke, C., McKinnon, T., Lightstone, L., Pickering, M. C., Thomas, D., McAdoo, S. P., & Willicombe, M. K. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.09.010 · Cited by 8
Antibody profiles in COVID ‐19 convalescent plasma prepared with amotosalen/ UVA pathogen reduction treatment
Bagri, A., de Assis, R. R., Tsai, C., Simmons, G., Mei, Z. W., von Goetz, M., Gatmaitan, M., Stone, M., Germanio, C. D., Martinelli, R., et al. (2022) · Transfusion · doi:10.1111/trf.16819 · Cited by 8
Serum peptidome profiles immune response of COVID-19 Vaccine administration
Zhang, W., Li, D., Xu, B., Xu, L., Lyu, Q., Liu, X., Li, Z., Zhang, J., Sun, W., Ma, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956369 · Cited by 8
SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors
Duan, L., Cui, X., Zhu, K.-L., Lin, Y., Wang, G., Cao, W., & Ma, M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111284 · Cited by 8
Identification of an immunogenic epitope and protective antibody against the furin cleavage site of SARS-CoV-2
Li, L., Gao, M., Li, J., Xie, X., Zhao, H., Wang, Y., Xu, X., Zu, S., Chen, C., Wan, D., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104401 · Cited by 8
Self-citation
Correlation of Automated Chemiluminescent Method with Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titers in Convalescent COVID-19 Plasma Samples: Development of Rapid, Cost-Effective Semi-Quantitative Diagnostic Methods
Mendoza, R., Silver, M. P., Zuretti, A. R., Christian, M., Das, B., Norin, A. J., Borgen, P. I., Libien, J. M., & Bluth, M. H. (2021) · Journal of Blood Medicine · doi:10.2147/jbm.s296730 · Cited by 8
Immunological and metabolic characteristics of the Omicron variants infection
Geng, J., Yang, X., Wang, K., Wang, K., Chen, R., Chen, Z., Qin, C., Wu, G., Wang, Y., Xu, K., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01265-8 · Cited by 9
Self-citation
Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection
Li, E., Han, Q., Bi, J., Wei, S., Wang, S., Zhang, Y., Liu, J., Feng, N., Wang, T., Wu, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1066730 · Cited by 9
Self-citation
Stability of SARS-CoV-2 in cold-chain transportation environments and the efficacy of disinfection measures
Peng, S., Li, G., Lin, Y., Guo, X., Xu, H. M., Qiu, W., Zhu, H., Zheng, J., Sun, W., Hu, X., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1170505 · Cited by 8
Structure-activity relationship studies in substituted sulfamoyl benzamidothiazoles that prolong NF-κB activation
Shukla, N. M., Chan, M., Lao, F. S., Chu, P. J., Belsuzarri, M. M., Yao, S., Nan, J., Sato-Kaneko, F., Saito, T., Hayashi, T., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116242 · Cited by 8
Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays
Curreli, F., Ahmed, S., Victor, S. M. B., Drelich, A. K., Panda, S. S., Altieri, A., Kurkin, A. V., Tseng, C.-T. K., Hillyer, C. D., & Debnath, A. K. (2021) · Viruses · doi:10.3390/v14010069 · Cited by 9
Evaluation of Immunogenicity by Pseudovirus Neutralization Assays for SARS‐CoV‐2 Variants after Primary and Booster Immunization
Xie, H., Wen, X., Li, J., Chen, W., Chen, M., Zhang, L., Lv, M., Zhou, S., Bai, S., Zhao, W., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.01.068 · Cited by 8
Self-citation
Evaluation of humoral immune responses induced by different SARS‐CoV‐2 spike trimers from wild‐type and emerging variants with individual, sequential, and combinational delivered strategies
Ding, C., Ni, S., Zhang, X., Xie, J., Sun, Y. C., He, J., Mei, Q., Huang, L., He, H., Liu, Z., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28081 · Cited by 8
Pseudovirus-Based Neutralization Assays as Customizable and Scalable Tools for Serological Surveillance and Immune Profiling
Denani, C. B., Setatino, B. P., Pereira, D., Horbach, I. S., Azevedo, A. D. S., Coutinho, G., Ferroco, C. L. D. V., Xavier, J. R., Leite, R., dos Santos, E. A. P., et al. (2025) · Pathogens · doi:10.3390/pathogens14111129 · Cited by 7
Peptide enzyme‐linked immunosorbent assay (pELISA) as a possible alternative to the neutralization test for evaluating the immune response to IBV vaccine
Wu, Q., Lin, Z., Wu, J., Qian, K., Shao, H., Ye, J., & Qin, A. (2021) · BMC Veterinary Research · doi:10.1186/s12917-021-02757-5 · Cited by 7
Self-citation
Establishment of national standard for anti-SARS-Cov-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard
Guan, L., Mao, Q., Tan, D., Liu, J., Zhang, X., Li, L., Liu, M., Wang, Z., Cheng, F., Cui, B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107639 · Cited by 7
Self-citation
Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSVMT) in golden syrian hamster
Ke, Y., Zhang, E., Guo, J., Zhang, X., Wang, L., Chen, D., Fang, X., Zhu, J., Li, F., Sun, T., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.08.023 · Cited by 7
Antigenic analysis of the influenza B virus hemagglutinin protein
Zhang, M., Yang, C., Wu, X., Wang, Y., Wang, L., Cui, Q., Tong, J., An, Y., Cai, M., Cheng, S., et al. (2024) · Virologica Sinica · doi:10.1016/j.virs.2024.08.012 · Cited by 7
Self-citation
Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19
Zhou, Z., Zhang, X., Li, Q., Fu, L., Wang, M., Liu, S., Wu, J., Nie, J., Zhang, L., Zhao, C., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.103 · Cited by 7
Self-citation
A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies
Mravinacová, S., Jönsson, M., Christ, W., Klingström, J., Yousef, J., Hellström, C., Hedhammar, M., Havervall, S., Thålin, C., Pin, E., et al. (2021) · New Biotechnology · doi:10.1016/j.nbt.2021.10.002 · Cited by 7
Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes
Hein, S., Benz, N. I., Eisert, J., Herrlein, M., Oberle, D., Dreher, M., Stingl, J., Hildt, C., & Hildt, E. (2021) · Vaccines · doi:10.3390/vaccines9121419 · Cited by 7
Aggregation of high‐frequency RBD mutations of SARS‐CoV‐2 with three VOCs did not cause significant antigenic drift
Li, T., Cui, Z., Jia, Y., Liang, Z., Nie, J., Zhang, L., Wang, M., Li, Q., Wu, J., Xu, N., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27596 · Cited by 8
Self-citation
Construction of SARS-CoV-2 spike-pseudotyped retroviral vector inducing syncytia formation
Lee, S. Y., Kim, D. W., & Jung, Y. T. (2022) · Virus Genes · doi:10.1007/s11262-022-01890-z · Cited by 7
A New iNKT-Cell Agonist-Adjuvanted SARS-CoV-2 Subunit Vaccine Elicits Robust Neutralizing Antibody Responses
Li, Y., Yan, C., Wang, X., Xian, M.-Y., Zou, G.-Q., Gao, X.-F., Luo, R., & Liu, Z. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00296 · Cited by 7
Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening
Hu, X., Cui, J., Chen, J., Du, S., Wang, X., Zhang, Y., Qian, J., Chen, H., Fang, W., Cai, Q., et al. (2022) · Virus Research · doi:10.1016/j.virusres.2022.198915 · Cited by 7
Self-citation
An Engineered IgG–VHH Bispecific Antibody against SARS‐CoV‐2 and Its Variants
Chi, H., Wang, L., Liu, C., Cheng, X., Zheng, H., Lv, L., Tan, Y., Zhang, N., Zhao, S.-Q., Wu, M., et al. (2022) · Small Methods · doi:10.1002/smtd.202200932 · Cited by 8
Long‐term SARS‐CoV‐2 neutralizing antibody level prediction using multimodal deep learning: A prospective cohort study on longitudinal data in Wuhan, China
Fang, C., Yan, W., Chen, Y., Dou, Z., Liu, T., Luo, F., Chen, W., Li, X., Chen, Y., Wu, W., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29036 · Cited by 8
Self-citation
Trivalent mRNA Vaccine against SARS-CoV-2 and Variants with Effective Immunization
Wang, J., Zhang, Y., Liu, C., Zha, W., Dong, S., Wang, Y., Jiang, Y., Xing, H., & Li, X. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00860 · Cited by 7
Self-citation
Systematical assessment of the impact of single spike mutations of SARS-CoV-2 Omicron sub-variants on the neutralization capacity of post-vaccination sera
Katzmarzyk, M., Clesle, D. C., van den Heuvel, J., Hoffmann, M., Garritsen, H., Pöhlmann, S., Jacobsen, H., & Čičin‐Šain, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1288794 · Cited by 7
Rapid and Quantitative In Vitro Evaluation of SARS-CoV-2 Neutralizing Antibodies and Nanobodies
Wu, W., Tan, X., Zupancic, J. M., Schardt, J. S., Desai, A. A., Smith, M. D., Zhang, J., Xie, L., Oo, M. K. K., Tessier, P. M., et al. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c00062 · Cited by 7
A replication-competent smallpox vaccine LC16m8Δ-based COVID-19 vaccine
Sakamoto, A., Osawa, H., Hashimoto, H., Mizuno, T., Hasyim, A. A., Abe, Y.-I., Okahashi, Y., Ogawa, R., Iyori, M., Shida, H., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2122580 · Cited by 7
Performance evaluation of newly developed surrogate virus neutralization tests for detecting neutralizing antibodies against SARS-CoV-2
Kweon, O. J., Bae, J., Lim, Y. K., Choi, Y., Lee, S., Park, M., Suh, I. B., Kim, H., Jee, Y. S., & Lee, M.-K. (2023) · Scientific Reports · doi:10.1038/s41598-023-31114-9 · Cited by 7
Actualización de la Declaración de consenso en medicina critica para la atención multidisciplinaria del paciente con sospecha o confirmación diagnóstica de COVID-19
Mendoza, J. L., Estrada, V. H. N., López, N. B., Bolaños, E. R., Franco, D. M., Castell, C. R. D., Moreno, A. A. V., Amaya, I., Flórez, J. S., VALENCIA, B. A. G., et al. (2020) · Acta Colombiana de Cuidado Intensivo · doi:10.1016/j.acci.2020.09.004 · Cited by 8
SARS-CoV-2 Omicron BA.2.86: less neutralization evasion compared to XBB sub-variantsPreprint
An, Y., Zhou, X., Tao, L., Xie, H., Li, D., Wang, R., Hu, H., Xu, Z., Dai, L., Xu, K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.26.559580 · Cited by 7
Establishment of a Novel Platform for Developing Oral Vaccines Based on the Surface Display System of Yeast Spores
Si, C., Bai, J., Li, Y., Li, Y., Liu, Y., Zhou, X., Shi, J., Hideki, N., & Li, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083615 · Cited by 6
A Comprehensive Technology Platform for the Rapid Discovery of Peptide Inhibitors against SARS-CoV-2 Pseudovirus Infection
Beeg, M., Baroni, S., Piotti, A., Porta, A., Luigi, A. D., Cagnotto, A., Gobbi, M., Diomede, L., & Salmona, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512146 · Cited by 6
Pediatric population (aged 3-11 years) received primary inactivated SARS-CoV-2 vaccination prior to infection exhibiting robust humoral immune response following infected with Omicron variant: a study conducted in Beijing
Li, J., Li, J., Dai, S., Dang, L., Wang, L., Cao, L., Chen, X., Wang, Y., Ge, M., Liu, W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1269665 · Cited by 6
Self-citation
Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.
Chen, G., Yu, X., Luo, L., Zhang, F., Dai, X.-H., Li, N., Shen, Z.-W., Wu, K.-Q., Lou, D., Peng, C.-G., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.065 · Cited by 6
Development of a SARS‐CoV‐2 neutralization assay based on a pseudotyped virus using a HIV system
Liang, Z., Tong, J., Wu, X., Liu, S., Wu, J., Yu, Y., Zhang, L., Zhao, C., Lu, Q., Nie, J., et al. (2024) · MedComm · doi:10.1002/mco2.517 · Cited by 6
Self-citation
A chimeric mRNA vaccine of S-RBD with HA conferring broad protection against influenza and COVID-19 variants
Hao, T.-J., Li, Y.-L., Liu, P., Wang, X., Xu, K., Lei, W.-W., Li, Y., Zhang, R., Li, X., Zhao, X., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012508 · Cited by 5
Self-citation
Compound screen identifies the small molecule Q34 as an inhibitor of SARS-CoV-2 infection
Cui, Q., Garcia, G., Zhang, M., Wang, C., Li, H., Zhou, T., Sun, G., Arumugaswami, V., & Shi, Y. (2021) · iScience · doi:10.1016/j.isci.2021.103684 · Cited by 6
Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations
Hu, C., Li, D., Liu, Z., Ren, L., Su, J., Zhu, M., Feng, Y., Wang, Z., Liu, Q., Zhu, B., et al. (2022) · Pathogens · doi:10.3390/pathogens11020171 · Cited by 7
Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2
Zhang, T., Zheng, N., Wang, Z., & Xu, X. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2174755 · Cited by 6
Engineering a NanoBiT biosensor for detecting angiotensin-converting enzyme-2 (hACE2) interaction with SARS-CoV-2 spike protein and screening the inhibitors to block hACE2 and spike interaction
Lin, C., Yang, X., Lin, M. C., Chang, H.-J., Lin, C., & Lin, C. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116630 · Cited by 6
Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains. Zhou et al.
Kwong, P. D. (2020) · Data Archiving and Networked Services (DANS) · doi:10.17632/y2j4k2mkd6 · Cited by 6
Consequences of Phosphorylation in a Mononegavirales Polymerase-Cofactor System
Gould, J. R., Qiu, S., Shang, Q., Dokland, T., Ogino, T., Petit, C. M., & Green, T. J. (2021) · Journal of Virology · doi:10.1128/jvi.02180-20 · Cited by 6
Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron
Zhu, K.-L., Gao, H., Lin, Y., Rong, J., Li, Y., Zhang, Z., Jiang, P., Duan, L., Wang, G., Dai, E., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac149 · Cited by 6
Discovery of dual S-RBD/NRP1-targeting peptides: structure-based virtual screening, synthesis, biological evaluation, and molecular dynamics simulation studies
Hu, C., Guo, T., Zou, Y., Gao, J., Gao, Y., Niu, M., Xia, Y., Shen, X., & Li, J. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2212327 · Cited by 6
Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against Wuhan-WT, delta and omicron BA1, BA2 spike trimers
Cheedarla, N., Verkerke, H., Potlapalli, S., McLendon, K. B., Patel, A. B., Frank, F., O’Sick, W., Cheedarla, S., Baugh, T., Damhorst, G. L., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108256 · Cited by 6
Review on current race for Covid-19 diagnosis
Karki, K., Priyadarshini, S., Kumar, P., Kumar, S., Kundu, R. S., Singh, K. P., Lather, A. S., Poonia, K., & Nehra, A. (2023) · Biosensors and Bioelectronics X · doi:10.1016/j.biosx.2023.100432 · Cited by 6
Intensive diagnostic management of coronavirus disease 2019 (COVID-19) in academic settings in Japan: challenge and future
Hoshina, T., Aonuma, H., Oté, M., Sakurai, T., Saiki, E., Kinjo, Y., Kondo, K., Okabe, M., & Kanuka, H. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00147-2 · Cited by 6
Identification of four linear B-cell epitopes on the SARS-CoV-2 spike protein able to elicit neutralizing antibodiesPreprint
Li, L., Zhao, Z., Yang, X., Li, W., Chen, S., Sun, T., Wang, L., He, Y., Liu, G., Han, X., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.13.422550 · Cited by 6
Self-citation
Heterologous vaccination strategy for containing COVID-19 pandemicPreprint
Lin, A., Liu, J., Ma, X., Zhao, F., Yu, B., He, J., Shen, M., Huang, L., Tang, H., Jiang, E., et al. (2021) · medRxiv · doi:10.1101/2021.05.17.21257134 · Cited by 6
Self-citation
Hyperglycemia induced cathepsin L maturation linked to diabetic comorbidities and COVID-19 mortality
He, Q., Zhao, M., Li, M.-J., Li, X., Jin, J., Feng, Y., Zhang, L., Huang, W., Yang, F., & Yang, J. (2024) · eLife · doi:10.7554/elife.92826 · Cited by 5
Self-citation
Large-scale validation of a plasmonic sensor for SARS-CoV-2 pseudo-neutralization with a cohort of food and retail workers
Coutu, J., Ricard, P., Djaïleb, A., Lavallée, É., Rabezanahary, H., Stuible, M., Durocher, Y., Gilbert, C., Brousseau, N., Santerre, K., et al. (2024) · Sensors & Diagnostics · doi:10.1039/d3sd00333g · Cited by 5
Safety and Immunogenicity of a PHH-1V Booster Dose after Different Prime Vaccination Schemes against Covid-19: Phase III Clinical Trial Final Results Up To One Year
Martinez, S., Ramos, R., Navarro-Pérez, J., Lopez, M. J., Vazquez, M. D. M., Moltó, J., Munoz, P., Echave, J. M., Arribas, J. R., Alvarez, M., et al. (2024) · Archives of Clinical and Biomedical Research · doi:10.26502/acbr.50170414 · Cited by 5
Pseudovirus as an Emerging Reference Material in Molecular Diagnostics: Advancement and Perspective
Zheng, L., & Xu, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080596 · Cited by 5
A SARS‐CoV‐2 Neutralization Assay Using Single Molecule Arrays
Gilboa, T., Cohen, L., Cheng, C., Lazarovits, R., Uwamanzu‐Nna, A., Han, I., Griswold, K., Barry, N., Thompson, D. B., Kohman, R. E., et al. (2021) · Angewandte Chemie · doi:10.1002/ange.202110702 · Cited by 5
The development of a rapid, high-throughput neutralization assay using a SARS-CoV-2 reporter
Suzuki, R., Kamiyama, A., Ito, H., Kawashiro, K., Tomiyama, T., Tamura, T., Suzuki, S., Yoshizumi, T., Hotta, K., & Fukuhara, T. (2024) · Journal of Virological Methods · doi:10.1016/j.jviromet.2024.114894 · Cited by 5
Laboratory tests for the detection of SARS-CoV-2 infection: basic principles and examples
Alkharsah, K. R. (2021) · PubMed Central · doi:10.3205/000293 · Cited by 5
Physiomimetic In Vitro Human Models for Viral Infection in the Liver
McDuffie, D., Barr, D., Helm, M., Baumert, T. F., Agarwal, A., & Thomas, E. (2022) · Seminars in Liver Disease · doi:10.1055/a-1981-5944 · Cited by 5
Optimization of the pseudoparticle system for standardized assessments of neutralizing antibodies against hepatitis C virus
Chumbe, A., Urbanowicz, R. A., Sliepen, K., Koekkoek, S. M., Molenkamp, R., Tarr, A. W., Ball, J., Schinkel, J., & van Gils, M. J. (2022) · Journal of General Virology · doi:10.1099/jgv.0.001801 · Cited by 5
Aptamer-based nanointerferometer enables amplification-free ultrasensitive detection and differentiation of SARS-CoV-2 variants
Chen, C., Song, X., Yu, Y., Wang, X., Xu, H., Ji, W., Ma, J., Zhao, C., Feng, S., Wang, Y., et al. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.341207 · Cited by 5
Self-citation
Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China
Yi, Y., Han, X., Cui, X., Wang, P., Wang, X., Liu, H., Wang, Y., Zhu, N., Li, Y., Lin, Y., et al. (2023) · Vaccines · doi:10.3390/vaccines11061019 · Cited by 5
Self-citation
Recent advances in health biotechnology during pandemic
Aslan, A., Alhamwı, S., Kurtur, O. B., GÜNDÜZ, O., Çakan, D., Üstündağ, C. B., Doymuş, B., Topuzoğulları, M., Yilmaz, B. B., Gök, B., et al. (2023) · Sigma Journal of Engineering and Natural Sciences – Sigma Mühendislik ve Fen Bilimleri Dergisi · doi:10.14744/sigma.2023.00065 · Cited by 5
AutoPlate: Rapid Dose-Response Curve Analysis for Biological Assays
Palmer, P., Rosario, J. M. M. D., da Costa, K. A. S., Carnell, G., Huang, C. Q., Heeney, J. L., Temperton, N. J., & Wells, D. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.681636 · Cited by 5
COVID-19 Diagnostics: A Panoramic View on Its Present Scenario, Challenges and Solutions
Quraishi, M., Upadhyay, S. K., & Nigam, A. (2022) · Proceedings of the National Academy of Sciences India Section B Biological Sciences · doi:10.1007/s40011-022-01375-x · Cited by 5
Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2
Balinsky, C. A., Jani, V., Sun, P., Williams, M., Defang, G. N., & Porter, K. R. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2111-0_21 · Cited by 5
A lateral flow test detecting SARS-CoV-2 neutralizing antibodiesPreprint
Zhang, N., Chen, S., Wu, J. V., Yang, X., & Wang, J. J. (2020) · medRxiv · doi:10.1101/2020.11.05.20222596 · Cited by 5
Self-citation
Development of a novel hybrid alphavirus-SARS-CoV-2 particle for rapid in vitro screening and quantification of neutralization antibodies, viral variants, and antiviral drugsPreprint
Hetrick, B., He, S., Chilin, L. D., Dabbagh, D., Alem, F., Narayanan, A., Luchini, A., Li, T., Liu, X., Copeland, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.22.423965 · Cited by 5
Effects and Mechanisms of Andrographolide for COVID-19: A Network Pharmacology-Based and Experimentally Validated Study
Zhang, J., Lü, H., Ruan, Y., Huang, S., Deng, S., Wang, Y., Li, Q., Zhao, Z., Feng, L., & Guo, W. (2024) · Natural Product Communications · doi:10.1177/1934578x241288428 · Cited by 4
Self-citation
Validation of an MLV-based SARS-CoV-2 pseudovirus neutralization assay substantiates L455S-mediated antibody escape
Moll, D., Springer, D. N., Weseslindtner, L., Aberle, S. W., Aberle, J. H., Medits, I., & Stiasny, K. (2026) · Scientific Reports · doi:10.1038/s41598-026-53146-7 · Cited by 4
Characterization of a Vesicular Stomatitis Virus-Vectored Recombinant Virus Bearing Spike Protein of SARS-CoV-2 Delta Variant
He, W., Cui, H. Y., Wang, S., Liang, B., Zhang, C., Wang, W., Wang, Q. M., Li, W., Zhao, Y., Wang, T., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11020431 · Cited by 4
Evolution of the newest diagnostic methods for COVID-19: a Chinese perspective
Liu, M., Lyu, J., Zheng, X., Liang, Z., Lei, B., Chen, H., Mai, Y., Huang, H., & Sun, B. (2023) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200625 · Cited by 4
Antiviral Effects of Secondary Metabolites from Jatropha podagrica Leaves against the Pseudotyped Virus of SARS-CoV-2 Omicron
Jang, Y. S., Lee, D. E., Ju, D. U., Jeong, S. Y., Ko, Y., Pang, C., Kang, K. S., Gwon, H., Yoo, H. M., & Kim, K. H. (2023) · Plants · doi:10.3390/plants12233942 · Cited by 5

Authors: Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., Lu, Q., Li, X., Sun, Q., Liu, J., Fan, C., Huang, W., Xu, M., & Wang, Y.
Affiliations: National Institutes for Food and Drug Control (CN)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author: Huang, Weijin
Xu, Miao
Wang, Youchun
ORCID: Nie, Jianhui
Li, Qianqian
Wu, Jiajing
Zhao, Chenyan
Liu, Huan
Zhang, Li
Nie, Lingling
Wang, Meng
Lu, Qiong
Li, Xiaoyu
Sun, Qiyu
Fan, Changfa
Huang, Weijin
Xu, Miao
Wang, Youchun
Venue: Emerging Microbes & Infections
Publisher: Informa UK Limited
Published: 2020-01
Volume: 9
Issue: 1
Pages: 680-686
ISSN: 2222-1751 (ISSN-L)
DOI: 10.1080/22221751.2020.1743767
PMC: PMC7144318
OpenAlex: W3012650581
Cited by: 711
References: 27
Citations by year: 2026: 21 · 2025: 37 · 2024: 73 · 2023: 95 · 2022: 157 · 2021: 186 · 2020: 141
FWCI: 19.06
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: Emerging Microbes & Infections (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords: SARS-CoV-2, pseudovirus neutralization assay, neutralizing antibodies, biosafety level 2, convalescent sera, assay validation, detection limit, cut-off values, COVID-19 treatment
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Serotherapy, Animals, Antibodies, Viral, Cell Line, Humans, Immune Sera, Immunization, Passive, Membrane Glycoproteins, Neutralization Tests, Plasmids, Pneumonia, Viral, Sensitivity and Specificity, Vesicular stomatitis Indiana virus, Viral Envelope Proteins, Reproducibility of Results, Coronavirus Infections, Mice, Virus Internalization, Antibodies, Neutralizing, Limit of Detection, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks